| Literature DB >> 28729308 |
Anneka Elizabeth Antoniak1, Carolyn A Greig1,2.
Abstract
OBJECTIVES: In older adults, there is a blunted responsiveness to resistance training and reduced muscle hypertrophy compared with younger adults. There is evidence that both exercise training and vitamin D supplementation may benefit musculoskeletal health in older adults, and it is plausible that in combination their effects may be additive. The aim of this systematic review was to evaluate the effectiveness of combined resistance exercise training and vitamin D3 supplementation on musculoskeletal health in older adults. DATA SOURCES: A comprehensive search of electronic databases, including Science Direct, Medline, PubMed, Google Scholar and Cochrane Central Register of Controlled Trials (Cochrane CENTRAL accessed by Wiley Science) was conducted. Eligible studies were randomised controlled trials including men and women (aged ≥65 years or mean age ≥65 years); enlisting resistance exercise training and vitamin D3 supplementation; including outcomes of muscle strength, function, muscle power, body composition, serum vitamin D/calcium status or quality of life comparing results with a control group. The review was informed by a preregistered protocol (http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015020157).Entities:
Keywords: Bone diseases; GERIATRIC MEDICINE; Musculoskeletal disorders; NUTRITION & DIETETICS; Physiology; SPORTS MEDICINE
Mesh:
Substances:
Year: 2017 PMID: 28729308 PMCID: PMC5541589 DOI: 10.1136/bmjopen-2016-014619
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Example Ovid Medline search, to be adapted for other databases
| 1 | Aging/ |
| 2 | Exp aged/ |
| 3 | (65 adj2 (years or age* or old*)) |
| 4 | (old* adj (adult* or people or person* or population* or men or women)) |
| 5 | (elder* or senior* or geriatric* or ?enarian or ag?ing) |
| 6 | ((age* or aging or old* or elder*) adj1 (musc*)) |
| 7 | 1 or 2 or 3 or 4 or 5 or 6 |
| 8 | Vitamin D/ |
| 9 | (cholecalciferol* or calciferol* or ergocalciferol*) |
| 10 | (supplements or dietary supplements) |
| 11 | ((vitamin D* or cholecalciferol or calciferol* OR ergocalciferol) adj supplementation) |
| 12 | 8 or 9 or 10 or 11 |
| 13 | Muscle Development/ |
| 14 | Muscle, Skeletal/ |
| 15 | (Skeletal muscle adj2 (atrophy or sarcopenia or wasting or loss or deterioration)) |
| 16 | Muscle Strength/ |
| 17 | (skeletal muscle mass or size or fibres or fibers or area) |
| 18 | (musc* adj2 (function* or power or strength)) |
| 19 | (musc* adj2 (grow* or hypertrophy or size or mass or csa or cross sectional area or volume)) |
| 20 | Body Composition/ |
| 21 | (lean adj3 mass) |
| 22 | (protein adj2 (turnover or synthesis or breakdown)) |
| 23 | (nitrogen adj2 (balance or turnover or synthesis or breakdown or retention or loss or retain*)) |
| 24 | Sarcopenia/ |
| 25 | 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 |
| 26 | Exp exercise/ |
| 27 | (resistance exercise or resistance exercise training) |
| 28 | ((resistance or strength or weight or cardio or aerobic) adj3 (train* or condition* or exercise* or lift*)) |
| 29 | (physical adj3 (activit* or exercise* or train* or exertion* or endurance* or therap* or conditioning or fitness)) |
| 30 | (exercise adj3 (train* or intervention* or protocol* or program* or therap* or regim* or activit*)) |
| 31 | 26 or 27 or 28 or 29 or 30 |
| 32 | 7 and 12 and 25 and 31 |
| 33 | Limit 32 to humans |
| 34 | Remove duplicates from 33 |
Figure 1Study flow chart.
Study demographics
| Author, year | N included in analyses | Mean age (y) | Sex (M:F) | Study design | Intervention group protocol | Control group protocol | Duration |
| Group 1: all participants exercised, intervention group received vitamin D supplementation | |||||||
| Agergaard | 17 | 66.9 | 17:0 | RCT | RET | RET | 16 weeks |
| Group 2: all participants received vitamin D supplementation, intervention group exercised | |||||||
| Drey | 45 | 77 | 13:32 | RCT | RET | Sedentary | 12 weeks |
| Gianoudis | 162 | 67 | 119:43 | RCT | HV-PRT | Sedentary | 12 months |
| Jessup | 18 | 69 | 0:18 | RCT | RET | Sedentary | 32 weeks |
| Verschueren | 111 | 79 | 0:111 | RCT | WBV | Sedentary | 6 months |
| Assigned to groups 1 and 2: participants took part in a combination of exercise and vitamin D interventions | |||||||
| Bunout | 92 | 77 | 9:83 | RCT | RET | RET | 9 months |
| Uusi-Rasi | 409 | 74 | 0:409 | RCT | RET 2x/week for 12 months, 1x/week for next 12 months or sedentary | RET 2x/week for 12 months, 1x/week for next 12 months or sedentary | 2 years |
*RCT, randomised controlled trial, RET, resistance exercise training, IU, international units, Ca, calcium, HV-PRT, high-velocity progressive resistance training; WBV, whole body vibration.
Summary of included study outcome measures and significant results
| Author, year | Outcome measures | Significant results | |
| Agergaard | Muscle strength | Isometric knee extensor (strain gauge) | Muscle strength: no between-group difference |
| Bunout | Muscle strength | Quadriceps (table) and hand grip strength (dynamometer) | Muscle strength: increased with exercise (p<0.001), no effect of vitamin D |
| Drey | Muscle power | Lower limb sit-to-stand transfer power (force plate) | Muscle power: increased with vitamin D intake (p=0.017) |
| Gianoudis | Muscle strength | Lower limbs (bilateral leg press) | Muscle strength: intervention increased strength relative to controls (p<0.001) |
| Jessup | Muscle strength | Hand grip (dynamometer), mean of 8 tests (stack machine) | Muscle strength: increased with intervention (p=0.0156) |
| Uusi-Rasi | Muscle strength | Max isometric leg extensor strength at a knee angle of 110° | Muscle strength: increased with exercise (p<0.001) Vitamin D supplementation N/S |
| Verschueren | Muscle strength | Isometric and dynamic knee extensor strength | Muscle strength: isometric: N/S Dynamic: N/S Vitamin D=no effect |
aLM, appendicular Lean Mass; BMD, bone mineral density; CSA, cross-sectional area; DXA, dual-energy X-ray absorptiometry; N/S, not significant; SPPB, short physical performance battery; SF-LLFDI, Short Form of the Late-Life Function and Disability Instrument; TUG, timed up and go.
Summary of risk of bias analysis for each included study
| Author, year | Components of risk of bias | Summary | Comments on high-risk components | ||||||
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | |||
| Agergaard | L | U | L | L | U | L | L | High (0) | N/A |
| Bunout | L | U | U | U | U | U | U | High (0) | N/A |
| Drey | L | L | U | U | L | L | U | High (0) | N/A |
| Gianoudis | L | U | U | U | H | L | L | High (1) | One high-risk component, 5 |
| Jessup | L | U | U | U | U | U | L | High (0) | N/A |
| Uusi-Rasi | L | U | U | U | U | L | L | High (0) | N/A |
| Verschueren | L | U | U | U | U | L | L | High (0) | N/A |
ITT, intention to treat; N/A, not available.
Figure 2Group 1 analysis of muscle strength of the lower limb.
Figure 6Group 2 analysis of the SPPB test.
Figure 7Group 2 analysis of the timed up and go test.
Figure 8Group 2 analysis of the muscle strength of the lower limb.
Figure 9Group 2 analysis of hand grip strength.
Figure 10Group 2 analysis of total body weight.
Figure 11Group 2 analysis of lean mass.
Figure 12Group 2 analysis of fat mass.
Figure 13Group 2 analysis of bone mineral density of the femoral neck.
Figure 14Group 2 analysis of bone mineral density of the spine.
GRADE analysis of group 1 measurement outcomes included in the quantitative synthesis
| Quality assessment |
| ||||||||||
| Outcome | Included studies (design) | ROB | Inconsistency | No serious Indirectness | Imprecision | Publication bias | Groups (intervention/control) | Effect size (direction) | p Value | 95% CI | Quality |
| Muscle strength (lower limb) | (RCT) | No serious ROB | Serious inconsistency (substantial heterogeneity) | No serious indirectness | No serious imprecision | Undetected^ | 131/135 | 0.98 (intervention) | <0.00001 | (0.73 to 1.24) | ⊕⊕⊕○ |
| TUG | (RCT) | No serious ROB | No serious inconsistency | No serious indirectness | Serious imprecision (CIs crossline of no effect/ OIS not reached) | Undetected^ | 124/125 | 0.37 (intervention) | 0.37 | (−0.68 to 0.26) | ⊕⊕⊕○ |
| BMD (femoral neck) | (RCT) | No serious ROB | No serious inconsistency | No serious indirectness | Serious imprecision (CIs crossline of no effect/ OIS not reached) | Undetected^ | 124/125 | 0.02 (intervention) | 0.15 | (−0.01 to 0.05) | ⊕⊕⊕○ |
| BMD (spine) | (RCT) | No serious ROB | No serious inconsistency | No serious indirectness | Serious imprecision (CIs crossline of no effect/ OIS not reached) | Undetected^ | 124/125 | 0.02 (intervention) | 0.41 | (−0.03 to 0.07) | ⊕⊕⊕○ |
^ Insufficient
BMD, bone mineral density; RCT, randomised controlled trial; OIS, Optimal Information Size; ROB, Risk Of Bias.
GRADE analysis of group 2 measurement outcomes included in the quantitative synthesis
| Quality assessment | Summary of findings | ||||||||||
| Outcome | Design, included studies | ROB | Inconsistency | Indirectness | Imprecision | Publication bias | Groups (intervention/ control) | Effect size (direction) |
|
| Quality |
| SPPB | (RCT) | No serious ROB | No serious inconsistency | No serious indirectness | No serious imprecision | Undetected^ | 45/46 | 1.09 (intervention) | 0.02 | (0.15 to 2.03) | ⊕⊕⊕⊕ |
| TUG | (RCT) | No serious ROB | No serious inconsistency | No serious indirectness | No serious imprecision | Undetected^ | 124/126 | −1.57 (intervention) | p=0.001 | (−2.50 to –0.64) | ⊕⊕⊕⊕ |
| Muscle strength (lower limb) | (RCT) | No serious ROB | Serious inconsistency (substantial heterogeneity) | No serious indirectness | No serious imprecision | Undetected^ | 124/126 | 2.69 (intervention) | 0.002 | (0.96 to 4.42) | ⊕⊕⊕○ |
| Hand grip strength | (RCT) | No serious ROB | No serious inconsistency | No serious indirectness | Serious imprecision (CI crossline of no effect, OIS not reached) | Undetected^ | 31/33 | 0.85 (intervention) | 0.55 | (−1.93 to 3.63) | ⊕⊕⊕○ |
| Weight | (RCT) | Serious ROB | No serious inconsistency | No serious indirectness | Serious imprecision (CI crossline of no effect, OIS not reached) | Undetected^ | 112/114 | −0.12 (intervention) | 0.37 | (−0.38 to 0.14) | ⊕⊕○○ |
| Lean mass | (RCT) | Serious ROB | No serious inconsistency | No serious indirectness | Serious imprecision (CI crossline of no effect, OIS not reached) | Undetected^ | 103/105 | 0.02 (intervention) | 0.98 | (−1.31 to 1.35) | ⊕⊕○○ |
| Fat mass | (RCT) | Serious ROB | No serious inconsistency | No serious indirectness | Serious imprecision (CI crossline of no effect, OIS not reached) | Undetected^ | 103/105 | −0.39 (intervention) | 0.76 | (−2.82 to 2.05) | ⊕⊕○○ |
| BMD (femoral neck) | (RCT) | Serious ROB | No serious inconsistency | No serious indirectness | No serious imprecision | Undetected^ | 124/126 | 0.04 (intervention) | 0.002 | (0.01 to 0.06) | ⊕⊕⊕○ |
| BMD (spine) | (RCT) | Serious ROB | Serious inconsistency (substantial heterogeneity) | No serious indirectness | Serious imprecision (CI crossline of no effect, OIS not reached) | Undetected^ | 124/126 | 0.02 (intervention) | 0.24 | (−0.001 to 0.05) | ⊕○○○ |
^Insufficient data to produce funnel plots.
BMD, bone mineral density; RCT, randomised controlled trial; SPPB, short physical performance battery; TUG, timed up and go.
Narrative analysis summary of findings for group 1 secondary outcome measures
| Category | Outcome measure | Assessment point | Study | Intervention group % change from baseline | Control group % change from baseline | ||||
| M | SD | N | M | SD | N | ||||
| Body composition | CSA of quadriceps muscles (cm2) | 16 weeks | Agergaard | +4.94 | 5.28 | 7 | +8.46* | 6.80 | 10 |
Group 1 studies compared vitamin D3 supplementation and exercise training vs exercise alone.
* p < 0.05
CSA, cross-sectional area.
Narrative analysis summary of findings for group 2 primary outcome measures
| Category | Outcome | Assessment point | Study | Intervention group % change from baseline | Control group % change from baseline | ||||
| M | SD | N | M | SD | N | ||||
| Muscle strength | Isometric knee extensor strength (Nm) | 6 months | Verschueren | +3.01 | 2.67 | 28 | +0.11 | 3.18 | 28 |
| Muscle power | Sit-to-stand transfer power (W) | 12 weeks | Drey | +8.99* | 5.51 | 23 | +2.61 | 2.49 | 22 |
| Functional stair climbing muscle power (W) | 12 months | Gianoudis | +10.40* | 13.00 | 81 | +6.20 | 12.70 | 81 | |
| Muscle function | 30 s sit-to-stand (n. stands) | 12 months | Gianoudis | +18.30* | 23.60 | 81 | +2.70 | 17.2 | 81 |
| 5-time chair stand time (s) | 24 months | Uusi-Rasi | −6.95 | 2.50 | 102 | −3.49 | 3.30 | 102 | |
| Normal walking speed (m/s) | 24 months | Uusi-Rasi | −1.80 | 0.20 | 102 | −3.30 | 0.21 | 102 | |
| Endurance: 12 min walk (m) | 9 months | Bunout | +8.80 | 17.60 | 22 | +20.90 | 27.70 | 24 | |
| Balance | Romberg ratio (%) | 9 months | Bunout | +2.80 | 33.80 | 22 | −0.60 | 35.80 | |
| Four-square step test (s) | 12 months | Gianoudis | −12.00* | 14.10 | 81 | −5.20 | 14.90 | 81 | |
| Body sway (cm) | 32 weeks | Jessup | −26.39* | 0.52 | 9 | +2.90 | 0.49 | 9 | |
| Backwards walking (% able to complete) | 24 months | Uusi-Rasi | +25.47* | 13.59 | 102 | +9.48 | 15.58 | 102 | |
Group 2 compared vitamin D3 supplementation and exercise training vs vitamin D3 supplementation alone.
* p < 0.05
Narrative analysis summary of findings for group 2 secondary outcomes
| Category | Outcome measure | Assessment point | Study | Intervention group % change from baseline | Control group % change from baseline | ||||
| M | SD | N | M | SD | N | ||||
| Body composition | Appendicular lean mass (kg) | 12 weeks | Drey | +1.65 | 0.71 | 23 | +0.00 | 0.87 | 22 |
| Muscle mass of upper limb (cm3) | 6 months | Verschueren | −0.16 | 0.57 | 28 | −0.25 | 0.38 | 28 | |
| BMD of femoral neck (g/cm2) | 6 months | Verschueren | +0.71 | 0.42 | 28 | +0.99 | 0.51 | 28 | |
Group 2 compared vitamin D3 supplementation and exercise training vs vitamin D3 supplementation alone.
BMD, bone mineral density.